Compare Novo Nordisk A/S (NVO) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ProShares UltraPro QQQ ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while ProShares UltraPro QQQ ETF trades at $71.48. The key difference: Novo Nordisk A/S pays a 3.63% dividend while ProShares UltraPro QQQ ETF pays none, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | TQQQ | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $71.70 | $87.22 |
52-Week Low | $35.29 | $37.89 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
